B. Pitt, G. Williams, W. Remme, F. Martinez, J. Lopez-sendon et al., The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study, Cardiovascular Drugs and Therapy, vol.15, issue.1, pp.79-87, 2001.

B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez et al., Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction, New England Journal of Medicine, vol.348, issue.14, pp.1309-1321, 2003.

P. Rossignol, J. Menard, R. Fay, F. Gustafsson, B. Pitt et al., Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy, Journal of the American College of Cardiology, vol.58, pp.1958-66, 2011.

W. Iraqi, P. Rossignol, M. Angioi, R. Fay, J. Nuee et al., Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study, Circulation, vol.119, pp.2471-2480, 2009.

J. P. Ferreira, K. Duarte, G. Montalescot, B. Pitt, E. L. De-sa et al., Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study, Clin Res Cardiol, vol.107, pp.49-59, 2018.

J. P. Ferreira, A. Barros, B. Pitt, G. Montalescot, E. L. De-sa et al., Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial, Clin Res Cardiol Germany, vol.2018, issue.107, pp.1192-1195

G. Klappacher, P. Franzen, D. Haab, M. Mehrabi, M. Binder et al., Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis, Am J Cardiol, vol.75, pp.913-921, 1995.

B. Lopez, A. Gonzalez, S. Ravassa, J. Beaumont, M. U. Moreno et al., Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal, Journal of the American College of Cardiology, vol.65, pp.2449-56, 2015.

G. Montalescot, B. Pitt, E. Lopez-de-sa, C. W. Hamm, M. Flather et al., Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study, Eur Heart J, vol.35, pp.2295-302, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01738642

F. Zannad, F. Alla, B. F. Dousset, A. Perez, and B. Pitt, Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure, Circulation, vol.102, issue.22, pp.2700-2706, 2000.

C. A. Souders, S. L. Bowers, and T. A. Baudino, Cardiac fibroblast: the renaissance cell, Circulation research, vol.105, pp.1164-76, 2009.

P. Kong, P. Christia, and N. G. Frangogiannis, The pathogenesis of cardiac fibrosis, Cellular and Molecular Life Sciences, vol.71, issue.4, pp.549-574, 2013.

K. Nagao, T. Inada, A. Tamura, K. Kajitani, K. Shimamura et al., Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression, ESC Heart Failure, vol.5, issue.6, pp.1044-1051, 2018.

J. P. Ferreira, P. Rossignol, A. Pizard, J. L. Machu, T. Collier et al., Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure, Heart

M. Hayashi, T. Tsutamoto, A. Wada, T. Tsutsui, C. Ishii et al., Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction, Circulation, vol.107, pp.2559-65, 2003.

H. Izawa, T. Murohara, K. Nagata, S. Isobe, H. Asano et al., Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study, Circulation, vol.112, pp.2940-2945, 2005.

J. Radovan, P. Vaclav, P. W. , J. C. Michal, A. et al., Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction, Molecular and cellular biochemistry, vol.293, pp.71-79, 2006.

N. B. Host, S. S. Hansen, L. T. Jensen, D. Husum, and J. D. Nielsen, Thrombolytic therapy of acute myocardial infarction alters collagen metabolism, Cardiology, vol.85, pp.323-356, 1994.

P. Rossignol, N. Girerd, G. Bakris, O. Vardeny, B. Claggett et al.,

D. J. Veldhuisen, H. Shi, S. Spanyers, J. Vincent, R. Fay et al., Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia, European journal of heart failure, vol.19, pp.792-799, 2017.

A. Aimo, G. Vergaro, V. Castiglione, A. Barison, E. Pasanisi et al., Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure, JACC Heart failure, vol.5, pp.735-742, 2017.

P. Rubis, S. Wisniowska-smialek, E. Wypasek, B. Biernacka-fijalkowska, L. Rudnicka-sosin et al., Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy. Inflammation research : official journal of the European Histamine Research Society, vol.65, pp.941-949, 2016.

M. Gyongyosi, J. Winkler, I. Ramos, Q. T. Do, H. Firat et al., Myocardial fibrosis: biomedical research from bench to bedside, European journal of heart failure, vol.19, pp.177-191, 2017.

N. B. Host, L. T. Jensen, P. M. Bendixen, S. E. Jensen, O. G. Koldkjaer et al., The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction, The American journal of cardiology, vol.76, pp.869-73, 1995.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. Cleland et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J, vol.37, pp.2129-2200, 2016.

C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey et al., ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, Circulation, vol.136, pp.137-161, 2017.

B. Ibanez, S. James, S. Agewall, M. J. Antunes, C. Bucciarelli-ducci et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC), Eur Heart J, vol.39, pp.119-177, 2017.

A. Olivier, B. Pitt, N. Girerd, Z. Lamiral, J. L. Machu et al., Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial, European journal of heart failure, vol.19, pp.1186-1197, 2017.

A. D. Mcgavigan, J. Moncrieff, M. M. Lindsay, P. R. Maxwell, and F. G. Dunn, Time course of plasma markers of collagen turnover in patients with acute myocardial infarction, Heart (British Cardiac Society), vol.90, pp.1053-1057, 2004.

C. Adamopoulos, A. Ahmed, R. Fay, M. Angioi, G. Filippatos et al., Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial, Eur J Heart Fail, vol.11, pp.1099-105, 2009.

, Legend: BMI, body mass index; IQR, interquartile range

H. Hf and . Failure,

, MI, acute myocardial infarction; DBP, diastolic blood pressure; SBP, systolic blood pressure

, LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate

. Arb, A. Blocker, and . Bb,

H. Hf and . Failure,

, MI, acute myocardial infarction

, diastolic blood pressure; SBP, systolic blood pressure, DBP

, LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate

. Arb, A. Blocker, and . Bb, PIIINP, amino-terminal propeptide of type III procollagen; PINP, amino-terminal propeptide of type I

, PINP, amino-terminal propeptide of type I procollagen. OR, odds ratio

. Ci,

, Multivariate logistic model